Limbal Stem Cell Deficiency (LSCD)
0
Pipeline Programs
1
Companies
1
Clinical Trials
0
Approved Products
Pipeline by Development Stage
Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
0
0
Early DiscoveryClinical DevelopmentMarket
Competitive Landscape
1 companies ranked by most advanced pipeline stage
BRIM BiotechnologyTaiwan - Taipei
1 programBRM421 Ophthalmic Solution, 0.06%N/A1 trial
Active Trials
NCT07422389Available
Clinical Trials (1)
BRM421 Ophthalmic Solution in Patients With Limbal Stem Cell Deficiency
N/AAvailable
Phase Legend
Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available
Key Insights
1 companies competing in this space